Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07730281
PHASE2

PRA-216 COPD Safety and Biomarker Study

Sponsor: Prana Therapies Inc

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).

Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-08-01

Completion Date

2027-09-01

Last Updated

2026-07-28

Healthy Volunteers

No

Interventions

DRUG

PRA-216

biologic

DRUG

Placebo

matching placebo for PRA-216